For primary hyperlipidemia. ANDA 206070, held by Mylan. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 206070 (Pitavastatin Calcium), held by Mylan, was first approved by FDA on Apr 4, 2019, with 2 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 4, 2019 | Original application | Approved | None posted |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Sep 27, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 29, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 4, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters